Dalia received her first degree in Biology from the University of León (Spain, 2012).
After a short period working as graduate with her own proyect "New antidepressive tarjets", in Neurobiological basis of the mechanism group (IP, Ángel Pazos, IBBTEC, Cantabria), she acquired experience over more than one year, followed by a private company (Genetracer Biotech, Cantabria) funded by Banco Santander CRUE-CEPYME 2015 Grants.
She got interested in the biomedical research area obtaining Master`s degree of Initiation to Mental Health Research (University of Cantabria, 2015).
Since 2017, Dalia has been working as a predoctoral student in Spatial regulation of Ras-ERK signals in cancer Group (IP, Piero Crespo, IBBTEC, Cantabria) funded by CIBERONC.
Spatial Regulation of Ras-ERK Signals in Cancer
Research lines
-
Spatial regulation of Ras-ERK signals in physiological processes and in cancer
-
Development of antitumoral drugs targeting protein-protein interactions in the Ras-ERK pathway
Funding
-
“Nuevas dianas moleculares en la ruta Ras-ERK: potencial terapéutico en el cáncer de tiroides”. Asociación Española Contra el Cáncer (AECC). GCB141423113. Proyecto coordinado 2014-2019.
-
Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC). RD/12/0036/0033. 2012-2015.
-
“Proteínas Scaffold como moduladores de la resistencia a inhibidores de la ruta RAS-ERK en melanoma”. SAF-2015 63638R. 2016-2018.
-
Grupo incluido en: Centro de Investigación Biomédica en Red sobre el Cáncer (CIBERONC). (CB16/12/00436). 2017-2023.
-
“ERK spatial distribution and dimerization: implications in carcinogenesis”. RTI2018-096658B. 2019-2021.
-
“Repurposing MAPK inhibitors for the treatment of COVID-19”. Proyecto intramural CSIC. CSIC-COV19-095. 2020.
-
Grupo incluido en la Plataforma PTI SALUD GLOBAL-CSIC: SG2103031_2107300020.
-
“Reutilización de inhibidores de MAPK para el tratamiento de COVID-19”. G.CANTABRIA: 2020UIC22-PUB0008.
-
“Proteínas HOX como mediadores de la ruta RAS-ERK”. PID2021-126288OB-I00. 2022-2025. 294.000€. Investigador Principal.
-
“Desarrollo de un marcador de la respuesta terapéutica del melanoma BRAF positivo”. Proyectos de Prueba de Concepto PDC2022-133569-I00. 2023-2025.
